Tag: David J. Bearss

Tolero, AbbVie to explore venetoclax alvocidib combo for AML

pharmanewsdaily- August 19, 2018

Tolero Pharmaceuticals said that its cyclin-dependent kinase 9 (CDK9) inhibitor alvocidib will be combined with AbbVie leukemia drug venetoclax to evaluate their potential in their ... Read More